Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annua...
21 February 2020 - 12:30AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced the acceptance and presentation details of data being
presented at the American Society for Experimental
Neurotherapeutics (ASENT) 2020 Meeting. The meeting is being held
In Bethesda, MD on March 2nd through March 5th, 2020.
“These new data are important, and help further
elucidate the significance of the conditions we are treating in our
clinical trials and the potential for positive impact of Zygel, if
approved by the FDA,” said Joseph M. Palumbo, MD, FAPA,
MACPsych, Chief Medical Officer of Zynerba. “We are committed to
developing therapeutic interventions for children and adolescents
with a variety of debilitating neuropsychiatric conditions
including Fragile X syndrome and autism spectrum disorder.”
Accepted as poster and for presentation
during The ASENT Pipeline Datablitz Short Presentation
session
Poster Title: "Phase 2 BRIGHT (An open-label tolerability and
efficacy study of ZYN002 administered as a transdermal gel to
children and adolescents with autism spectrum disorder): Baseline
characteristics"Poster number: 27Poster reception: Tuesday, March 3
from 5:00 to 6:00 PM and Wednesday, March 4 from 5:00 to 7:00
PM.Presentation time: Wednesday, March 4 from 1:00 to 3:00 PM.
Poster Title: "Post-hoc Analysis - An open-label study of
transdermal cannabidiol (ZYN002) for the treatment of Fragile X
syndrome in children and adolescents: Estimating health state
utility scores"Poster number: 29Poster reception: Tuesday, March 3
from 5:00 to 6:00 PM and Wednesday, March 4 from 5:00 to 7:00
PM.Presentation time: Wednesday, March 4 from 1:00 to 3:00 PM.
Accepted as poster
Poster Title: "Fragile X syndrome diagnosis and patient journey:
The caregivers' perspective"Poster number: 28Poster reception:
Tuesday, March 3 from 5:00 to 6:00 PM and Wednesday, March 4 from
5:00 to 7:00 PM.
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare
neuropsychiatric disorders. We are committed to improving the lives
of patients and their families living with severe, chronic health
conditions including Fragile X syndrome, autism spectrum disorder,
22q11.2 deletion syndrome, and a heterogeneous group of rare and
ultra-rare epilepsies known as developmental and epileptic
encephalopathies. Learn more at www.zynerba.com and follow us on
Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Zynerba ContactWill Roberts, VP Investor
Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactMolly DevlinEvoke
KYNE215.928.2199Molly.Devlin@evokegroup.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2024 to May 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From May 2023 to May 2024